Adalimumab

Aka: Adalimumab, Humira

II. Indications

  1. Severe active Rheumatoid Arthritis refractory to DMARDs

III. Contraindications

  1. Chronic or acute infection
  2. Concurrent use of Interleukin-1 Receptor Antagonist
    1. Anakinra (Kineret)

IV. Mechanism: Monoclonal Antibody

  1. Human antitumor Necrosis Factor alpha
  2. Similar to Infliximab and Etanercept

V. Dosing

  1. Every other week: 40 mg SC

VI. Adverse Effects

  1. Immunosuppression
    1. Use caution in any patient prone to infection
  2. Headache
  3. Rash
  4. Hypertension
  5. Hyperlipidemia
  6. Injection site inflammation
  7. Gastrointestinal upset

VII. Cost

  1. Two 40 mg vials: $1200 (in 2003)

VIII. References

  1. (2003) Lexi-Comp Drug Database

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Adalimumab." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Cost: Medications

humira (on 2/22/2017 at Medicaid.Gov Survey of pharmacy drug pricing)
HUMIRA 40 MG/0.8 ML PEN $2,144.44 each
HUMIRA 40 MG/0.8 ML SYRINGE $2,147.09 each
HUMIRA PEN CROHN-UC-HS STARTER $2,158.48 each
HUMIRA PEN PSORIASIS-UVEITIS STARTER $2,158.52 each
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information.

Ontology: adalimumab (C1122087)

Definition (NCI) A recombinant, human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), with immunomodulating activity. Upon administration, adalimumab binds to TNF-alpha, thereby preventing its binding to the p55 and p75 TNF cell surface receptors and inhibiting TNF-mediated immune responses. TNF-alpha, a pro-inflammatory cytokine, is upregulated in various autoimmune diseases.
Concepts Pharmacologic Substance (T121) , Immunologic Factor (T129) , Amino Acid, Peptide, or Protein (T116)
MSH C453439
SnomedCT 398728003, 407317001
LNC LP173592-9, MTHU047400
English adalimumab (medication), tumor necrosis factor alpha blockers adalimumab, ADALIMUMAB, adalimumab [Chemical/Ingredient], antibody d2e7, Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer, D2E7, adalimumab, D2E7 antibody, Adalimumab (product), Adalimumab, Adalimumab (substance)
Spanish adalimumab (producto), adalimumab, adalimumab (sustancia)
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Humira (C1171255)

Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) , Immunologic Factor (T129)
MSH C453439
LNC LA16779-3
English Humira, adalimumab (Humira), humira, Abbott brand of adalimumab
Derived from the NIH UMLS (Unified Medical Language System)

Related Topics in Pharmacology

2021 Family Practice Notebook, LLC. Terms | Privacy (EHS) | About | Site Map | Blog

Footer Site Logo